Drug Type Small molecule drug |
Synonyms Gingogink, Ginkgo biloba special extract, EGB 761 + [2] |
Target |
Mechanism NOS2 inhibitors(Nitric oxide synthase, inducible inhibitors), Platelet aggregation inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date FR (28 Feb 2002), |
Regulation- |
Molecular FormulaC11H13ClN2S |
InChIKeyLAZPBGZRMVRFKY-HNCPQSOCSA-N |
CAS Registry16595-80-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Nervous System Diseases | CN | 09 Mar 2007 | |
Alzheimer Disease | FR | 28 Feb 2002 |
Phase 3 | 3,069 | (Ginkgo Biloba) | mlmwtmzijr(xsaqapsnad) = tewvwjehyf oxepmbizjq (egscachjzw, sjesjogxng - fxmmeduhpq) View more | - | 16 Sep 2010 | ||
Placebo (Placebo) | mlmwtmzijr(xsaqapsnad) = hnutbejkel oxepmbizjq (egscachjzw, qaedjtqgfi - txiyavghww) View more | ||||||
Not Applicable | 410 | Ginkgo biloba extract EGb 761® 240 mg | kszslqugqj(ehmujrfvyh) = nrxnxngzgl nyhqkuihli (rlsewelvdr ) View more | Positive | 01 Jul 2008 | ||
Placebo | kszslqugqj(ehmujrfvyh) = fkoujhuqwo nyhqkuihli (rlsewelvdr ) View more |